FDA Recalls OxyTOCIN IV Bags Due to Sterility Assurance Issues
Central Admixture Pharmacy Services is recalling 497 bags of OxyTOCIN IV bags nationwide due to lack of validated sterility assurance. The manufacturer's decontamination validation data is insufficient.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of an injectable medication due to unvalidated sterilization process. No illnesses or injuries reported; hazard is theoretical based on lack of process validation.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 497 bags of OxyTOCIN 30 units in dextrose 5%/lactated ringers 500 mL IV bags distributed nationwide.
The recall was initiated due to lack of assurance of sterility. The manufacturer lacks sufficient validation data for its decontamination cycles, meaning the sterilization process has not been properly verified to ensure the product is sterile.
The affected product includes Lot 36-249712 (expiration 8/20/2023) and Lot 36-250059 (expiration 8/22/2023), both with NDC 72196-6032-1. Healthcare facilities should check their inventory for these lots and take appropriate action in consultation with their pharmacy and medical leadership.
The recalled product
- Product
- oxyTOCIN 30 units added to dextrose 5%/lactated ringers 500 mL, IV Bag, Rx Only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Pheonix, AZ 85043, NDC: 72196-6032-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Intravenous
- Hazard
- sterility
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot: 36-249712
- Exp. 8/20/2023
- 36-250059
- Exp. 8/22/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27